Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Karyopharm...

    Karyopharm Therapeutics gets USFDA nod for blood cancer drug Xpovio

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-07-07T09:45:48+05:30  |  Updated On 7 July 2019 9:45 AM IST
    Karyopharm Therapeutics gets USFDA nod for blood cancer drug Xpovio

    The drug Xpovio was approved in combination with dexamethasone for patients who have received at least four prior therapies and who fail to respond to certain other treatments, the agency said.


    New Delhi: The U.S. Food and Drug Administration on Wednesday approved Karyopharm Therapeutics Inc's treatment for multiple myeloma, a type of blood cancer.


    The drug Xpovio was approved in combination with dexamethasone for patients who have received at least four prior therapies and who fail to respond to certain other treatments, the agency said.


    "Sadly, often over time, patients can exhaust all available treatments and still see their disease progress," said Richard Pazdur, director of the FDA's Oncology Center of Excellence.


    Read Also: USFDA declines to approve Daiichi Sankyo blood cancer treatment Quizartinib


    Karyopharm said it expects Xpovio to become commercially available in the United States by July 10.


    The drug, chemically known as selinexor, binds to and inhibits a protein called XPO1, leading to the accumulation of cancer-suppressing proteins in the cells.


    The U.S. health regulator was to initially decide on the treatment's approval in April, but pushed back the date by three months to review additional data submitted by the company.


    Multiple myeloma is estimated to cause nearly 13,000 deaths in the United States in 2019, according to the American Cancer Society.

    blood cancerblood cancer drugcancerdrug XpovioKaryopharm Therapeuticsmultiple myelomapharmapharma newspharma news indiaRichard PazdurShares of Karyopharm TherapeuticsUnited StatesUSUSFDAXpovio
    Source : Reuters

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok